May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
Family Caregivers of Cancer Patients Vulnerable to Depression, Anxiety
Most US Adults Favor Prohibiting Tobacco Sales in Retail Pharmacies
Atezolizumab's Success in NSCLC Spells Further Trouble for Nivolumab